Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults
about
Vaccines for preventing typhoid feverVaccines against invasive Salmonella disease: current status and future directionsThe effects of vaccination and immunity on bacterial infection dynamics in vivoComplex adaptive immunity to enteric fevers in humans: lessons learned and the path forwardVaccines against enteric infections for the developing worldDevelopment of Vi conjugate - a new generation of typhoid vaccine.Stochastic simulation of endemic Salmonella enterica serovar Typhi: the importance of long lasting immunity and the carrier state.Glycoconjugate vaccine strategies for protection against invasive Salmonella infections.O:2-CRM(197) conjugates against Salmonella Paratyphi A.Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method.A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned.Glycoconjugate vaccines.Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development.An Overview of Structural Features of Antibacterial Glycoconjugate Vaccines That Influence Their Immunogenicity.Use of a novel antigen expressing system to study the Salmonella enterica serovar Typhi protein recognition by T cells.A multi-criteria decision making approach to identify a vaccine formulation.The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.Vaccines for enteric diseases: a meeting summary.Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
P2860
Q24201238-F2539DB7-4B1D-4320-BE3D-2DB866C279BEQ27007088-4FDA147C-CA4A-46C2-B9AA-B4EAD23EAFA7Q27324150-F355267C-C82E-4551-9ED9-A78F820FA4C4Q27694492-FEDC87ED-8D52-43DB-8BE6-628E4C93EF64Q28080866-B8218BC9-AE39-478B-A2C2-6A36E9223F84Q34380025-E7CDE31B-8BAC-4D95-819C-FD2CB2BE46D9Q34989762-2383AA2A-28E5-4A24-AD03-954725296385Q36184367-9254DDE2-132A-44F8-B82A-1185E2AB4C0EQ36380921-8B7BCFC6-D0B9-4A2E-BA85-546C979B52BEQ37094977-200BFABE-3CC3-4F82-A7C3-C412A1FEEFE0Q37340441-B9510ED7-D40B-4FF5-B21A-FA354C4909AAQ38044755-B72D6CB5-9985-49BE-8FDE-006CDFDD4436Q38140038-D2F37C0C-B756-4F88-8E7D-A14B5A35FED5Q39093233-3E3D3505-0E0A-430C-962F-AE4284D9C621Q40040654-453A2CB8-A556-4AFF-8B1E-1415AD358173Q41534119-240985D1-4B31-4558-A7EC-3200133A48A6Q47245287-9F5783B7-F4D4-4735-B009-29C98CABBA4AQ48008673-0E3DCDF3-0903-4377-9E10-404544BC5B79Q55278055-163BFC73-4442-4CF8-A540-40659437DB5E
P2860
Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Safety, immunogenicity and dos ...... ical testing in healthy adults
@ast
Safety, immunogenicity and dos ...... ical testing in healthy adults
@en
Safety, immunogenicity and dos ...... ical testing in healthy adults
@nl
type
label
Safety, immunogenicity and dos ...... ical testing in healthy adults
@ast
Safety, immunogenicity and dos ...... ical testing in healthy adults
@en
Safety, immunogenicity and dos ...... ical testing in healthy adults
@nl
prefLabel
Safety, immunogenicity and dos ...... ical testing in healthy adults
@ast
Safety, immunogenicity and dos ...... ical testing in healthy adults
@en
Safety, immunogenicity and dos ...... ical testing in healthy adults
@nl
P2093
P2860
P3181
P1433
P1476
Safety, immunogenicity and dos ...... ical testing in healthy adults
@en
P2093
Alessandra Anemona
Anne Katrin Hilbert
Audino Podda
Elisa Marchetti
Francesca Micoli
Froukje Kafeja
Ilse De Coster
Laura B Martin
Pierre van Damme
Rana M Qasim Khan
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0025398
P407
P577
2011-01-01T00:00:00Z